You are here

Somatuline Depot Approved to Treat Carcinoid Syndrome

Injection is also approved for GEP-NETs

Lanreotide injection (Somatuline Depot, Ipsen Biopharmaceuticals, Inc.) 120 mg has received FDA approval for a new indication: the treatment of carcinoid syndrome. When used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

The medication, a somatostatin analog, is also approved for the improvement of progression-free survival in patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The additional approval for carcinoid syndrome was based on “Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (ELECT): A Randomized, Double-Blind, Placebo-Controlled Trial,” published in Endocrine Practice.

In this 16-week, randomized, double-blind, phase 3 trial, patients with and without prior somatostatin analog use were randomized to lanreotide depot/autogel 120 mg or placebo every four weeks, with access to short-acting octreotide as rescue medication. The primary endpoint was the percentage of days in which short-acting octreotide was used, which was assessed by an analysis of daily diaries.

A total of 115 patients were enrolled (lanreotide, n = 59; placebo, n = 56). The adjusted mean percentage of days with rescue octreotide use was significantly lower in the lanreotide group (33.7%; 95% confidence interval [CI], 25.0%–42.4%) versus the placebo group (48.5%; 95% CI, 39.6%–57.4%). The odds ratio (OR) of full/partial treatment success (three days or less of short-acting octreotide use in weeks 12 to 15) was significantly greater with lanreotide than placebo (OR, 2.4; 95% CI, 1.1–5.3; P = .036).

Sources: Ipsen; September 18, 2017; Endocrine Practice; September 2016.

Recent Headlines

The answer may offer a potential treatment for the disease
Drug resistance in HIV patients has nearly tripled since 2001
Drug resistance in HIV patients has nearly tripled since 2001
New drug addresses bacterial resistance to standard therapy
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia
The number of those with an annual drug spend of $250K or more has increased by 60%
Grading manufacturers would give high-quality, reliable makers a boost, says federal panel
Sharpless is heading back to NCI